Headquartered in San Jose, CA Fiscal year ends December NASDAQ: PRCT procept-biorobotics.com
PROCEPT BioRobotics is a surgical robotics company focused on developing transformative solutions in urology. The company manufactures the AQUABEAM and HYDROS Robotic Systems, with the HYDROS being the only AI-powered robotic technology that delivers Aquablation therapy for the treatment of benign prostatic hyperplasia (BPH). BPH is the most common prostate disease, affecting approximately 40 million men in the United States. Aquablation therapy is designed to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms due to BPH, independent of prostate size, shape, or surgeon experience. The company combines AI, robotics, and real-time imaging to enable personalized and precise treatment. PROCEPT has built a significant body of clinical evidence with approximately 250 peer-reviewed publications supporting Aquablation therapy. The company is also advancing into prostate cancer treatment through its WATER IV clinical trial. Revenue is generated through system sales, handpieces and consumables, and service contracts, with operations in the U.S. and international markets. Updated
Pre-Market Stock Futures: Futures are trading higher after a dreadful day on Wall Street, when all the major indices traded lower, and we saw the same pattern that has developed over the…
It is tempting to believe the next Nvidia (NASDAQ:NVDA | NVDA Price Prediction) or Palantir (NASDAQ:PLTR) is hiding in plain sight and will quickly give you multibagger returns. It does happen, but…
PROCEPT BioRobotics is a surgical robotics company focused on developing transformative solutions in urology.
The Wall Street consensus 12-month price target for PRCT is $22.42.
